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insulin Resistance
n Chronic Heart Failure
n their recent study, Witteles and Fowler (1) highlight the impact
f insulin-resistant cardiomyopathy on development, clinical se-
erity, and progression of chronic heart failure (CHF). We would
ike to extend this important perspective on impaired insulin
ensitivity in CHF from a mere myocardial view to a generalized
spect within CHF pathophysiology.
It should be noted that insulin resistance observed in epidemio-
ogical studies in CHF patients refers always to the whole body rather
han to the myocardium alone. Skeletal muscle accounts for the
ajority of insulin-stimulated glucose uptake (2). Accordingly, most
uman studies as discussed by the authors assessed insulin resistance
by one way or another) of the whole body, and common mechanisms
f impaired glucose utilization in skeletal muscle and myocardium
ave been adopted. It is not clear whether the insulin resistance of the
yocardium has specific characteristics that are different and that
hould be viewed strictly separated from the skeletal muscle.
Extending the concept of insulin resistance beyond the myo-
ardium and involving whole-body impaired insulin sensitivity will
y no means diminish the significance of this impairment in energy
etabolism as a strong and independent contributor to CHF
orbidity and mortality (3,4). In fact, extending this concept
eflects the increasingly appreciated impact of peripheral factors
ontributing to CHF pathophysiology. In the prolonged course of
HF, (mal)adaptations to impaired perfusion result in intrinsic
tructural and functional changes in various organs and tissues,
uch as muscle tissue. This growing influence of the periphery on the
ymptoms (muscle fatigue, reduced power, dyspnea) and prognosis of
HF are emphasized in the muscle hypothesis (5). Given the strong
nabolic function of insulin, impaired global insulin sensitivity may be
vital underlying cause in the overall catabolic/anabolic imbalance in
HF, leading to tissue wasting and, eventually, to cardiac cachexia
6). Moreover, currently discussed therapeutic options to improve the
energy) metabolic efficiency exert systemic effects (i.e., on metabolism
n both the myocardium and skeletal muscle).
By extending the view on insulin resistance in CHF to the
hole body, pathophysiologic, symptomatic, prognostic, and ther-
peutic considerations are met more thoroughly.
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e thank Dr. Doehner and colleagues for their insightful com-
ents about our recent study (1). We agree that the peripheral
ffects of insulin resistance are likely also to have a major role in
he pathophysiology of heart failure (HF). It is clear that
yocardial energy metabolism is strongly influenced by both
ystemic and local myocardial factors.
As an example of systemic factors, peroxisome proliferator-
ctivated receptor (PPAR)- agonist treatment results in dramatic
yocardial metabolic changes (2), despite the fact that there is
ittle to no myocardial expression of the PPAR- receptor (3).
learly, the effects must be indirect, likely because of improve-
ents in whole-body insulin sensitivity and the resultant decrease
n circulating free fatty acids. As an example of local myocardial
actors, cardiac-specific overexpression of the GLUT1 receptor
revents HF in mice; this cannot be a systemic effect, as the
eceptor overexpression is restricted to the heart (4).
In addition to the direct role that insulin resistance plays in
eading to cardiomyopathy, a vicious cycle exists in which the
ormonal dysregulation and metabolic derangements of HF lead
o worsened whole-body insulin resistance, which in turn leads to
orsening of the metabolic derangements themselves. Not surpris-
ngly, therefore, worsened whole-body insulin resistance correlates
ith worsened outcomes in patients with HF (5). Whether
reating whole-body insulin resistance will positively affect HF
atients remains unclear, though preliminary evidence (6–8)
avors using metabolic-modulating agents, which specifically result
n increased myocardial glucose metabolism. Fortunately, most
ystemic treatments with metabolic modulators and/or insulin-
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July 15, 2008:239–40ensitizing agents will serve the best of both worlds: affecting
hole-body insulin sensitivity as well as cardiac metabolism.
We share the enthusiasm of Dr. Doehner and colleagues in urging
urther mechanistic/treatment studies to better define optimal treat-
ent of the insulin-resistant cardiomyopathy population.
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